- Home
- KRC vs AXSM Comparison
KRC vs AXSM Comparison
Compare KRC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRC
- AXSM
- Stock Information
- Founded
- KRC 1947
- AXSM 2012
- Country
- KRC United States
- AXSM United States
- Employees
- KRC N/A
- AXSM N/A
- Industry
- KRC Real Estate Investment Trusts
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- KRC Real Estate
- AXSM Health Care
- Exchange
- KRC Nasdaq
- AXSM Nasdaq
- Market Cap
- KRC 4.6B
- AXSM 4.4B
- IPO Year
- KRC 1997
- AXSM 2015
- Fundamental
- Price
- KRC $40.67
- AXSM $98.68
- Analyst Decision
- KRC Hold
- AXSM Strong Buy
- Analyst Count
- KRC 8
- AXSM 14
- Target Price
- KRC $39.43
- AXSM $124.93
- AVG Volume (30 Days)
- KRC 1.1M
- AXSM 568.5K
- Earning Date
- KRC 10-28-2024
- AXSM 11-12-2024
- Dividend Yield
- KRC 5.31%
- AXSM N/A
- EPS Growth
- KRC N/A
- AXSM N/A
- EPS
- KRC 1.67
- AXSM N/A
- Revenue
- KRC $1,118,266,000.00
- AXSM $338,457,000.00
- Revenue This Year
- KRC N/A
- AXSM $40.67
- Revenue Next Year
- KRC $0.36
- AXSM $69.27
- P/E Ratio
- KRC $24.34
- AXSM N/A
- Revenue Growth
- KRC N/A
- AXSM 51.47
- 52 Week Low
- KRC $29.72
- AXSM $60.28
- 52 Week High
- KRC $43.78
- AXSM $105.00
- Technical
- Relative Strength Index (RSI)
- KRC 55.89
- AXSM 62.20
- Support Level
- KRC $37.83
- AXSM $90.86
- Resistance Level
- KRC $42.10
- AXSM $99.35
- Average True Range (ATR)
- KRC 1.02
- AXSM 4.10
- MACD
- KRC -0.10
- AXSM 0.53
- Stochastic Oscillator
- KRC 66.51
- AXSM 66.63
About KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 17 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.